Disclosure

I have NO financial relationships to disclose.



Approach to Young Febrile Infants – Things Have Changed!

Johanna Kielbasa, MD July 23rd, 2022

Learning Objectives



"We are not makers of history. We are made by history."

> ~ Martin Luther King, Jr.



"There is nothing permanent except change."

~ Heraclitus

Updated Guidelines


"Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment."

~ Buddha



"In the middle of a difficulty lies opportunity."

~ Einstein



History (Fifty Decades)

- 1970s: Group B Streptococcus (GBS)
- 1980s: First guidelines, risks, and costs
- 1980s-1990s: Attempts to develop and validate prediction models
- 2000s: Lots more studies...

Clinical Trial > N Engl J Med. 1993 Nov 11;329(20):1437-41.

doi: 10.1056/NEJM199311113292001.

Outpatient management without antibiotics of fever in selected infants

M D Baker 1, L M Bell, J R Avner

Affiliations + expand

PMID: 8413453 DOI: 10.1056/NEJM199311113292001

Free article

Original articl

Outpa days o ceftria

MD Marc N. I

Abstract

Background: In many academic centers it is standard practice to hospitalize all febrile infants younger than two months of age, whereas in community settings such infants are often cared for as outpatients.

Methods: We conducted a controlled study of 747 consecutive infants 29 through 56 days of age who had temperatures of at least 38.2 degrees C. After a complete history taking, physical examination, and sepsis workup, the 460 infants with laboratory or clinical findings suggestive of serious bacterial illness were hospitalized and treated with antibiotics. The screening criteria for serious bacterial illness included a white-cell count of at least 15,000 per cubic millimeter, a spun urine specimen that had 10 or more white cells per high-power field or that was positive on brightfield microscopy, cerebrospinal fluid with a white-cell count of 8 or more per cubic millimeter or a positive Gram's stain, or a chest film showing an infiltrate. The 287 infants who had unremarkable examinations and normal laboratory results were assigned to either inpatient observation without antibiotics (n = 148) or outpatient care without antibiotics but with reexaminations after 24 and 48 hours (n = 139).

to 89 tion of

Chiltren

Learning Objectives



"We are not makers of history. We are made by history."

> ~ Martin Luther King, Jr.



"There is nothing permanent except change."

~ Heraclitus

Updated Guidelines

"Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment."

~ Buddha



"In the middle of a difficulty lies opportunity."

~ Einstein

Why Change?



- Changing bacteriology
- Cost of unnecessary care
- Advances in testing
 - Inflammatory markers
 - Pathogen identification
 - Viral testing
 - Emerging technologies
- Opportunities to improve the care of hospitalized infants
- Evolving research strategies

AND there is evidence to support the change...

Evidence for Age-Based Risk Stratification > JAMA. 2004 Mar 10;291(10):1203-12. doi: 10.1001/jama.291.10.1203.

Management and outcomes of care of fever in early infancy

Robert H Pantell ¹, Thomas B Newman, Jane Bernzweig, David A Bergman, John I Takayama, Mark Segal, Stacia A Finch, Richard C Wasserman

Affiliations + expand

PMID: 15010441 DOI: 10.1001/jama.291.10.1203

Results: The PROS clinicians hospitalized 36% of the infants, performed laboratory testing in 75%, and initially treated 57% with antibiotics. The majority (64%) were treated exclusively outside of the hospital. Bacteremia was detected in 1.8% of infants (2.4% of those tested) and bacterial meningitis in 0.5%. Well-appearing infants aged 25 days or older with fever of less than 38.6 degrees C had a rate of 0.4% for bacteremia/bacterial meningitis. Frequency of other illnesses included urinary tract infection, 5.4%; otitis media, 12.2%; upper respiratory tract infection, 25.6%; bronchiolitis, 7.8%; and gastroenteritis, 7.2%. Practitioners followed current guidelines in 42% of episodes. However, in the initial visit, they treated 61 of the 63 cases of bacteremia/bacterial meningitis with antibiotics. Neither current guidelines nor the model developed in this study performed with greater accuracy than observed practitioner management.

Observational Study > Ann Emerg Med. 2018 Feb;71(2):211-216.

doi: 10.1016/j.annemergmed.2017.07.488. Epub 2017 Oct 6.

Epidemiology of Bacteremia in Febrile Infants Aged 60 Days and Younger

Elizabeth C Powell 1, Prashant V Mahajan 2, Genie Roosevelt 3, John D Hoyle Jr 4, Rajender Gattu 5, Andrea T Cruz ⁶, Alexander J Rogers ², Shireen M Atabaki ⁷, David M Jaffe ⁸, T Charles Casper ⁹, Octavio Ramilo 10, Nathan Kuppermann 11,

Febrile Infant Working Group of the Pediatric Emergency Care Applied Research Network (PECARN)

Collaborators, Affiliations + expand

PMID: 28988964 PMCID: PMC5815881 DOI: 10.1016/j.annemergmed.2017.07.488

Evidence for Age-Based Risk Stratification

Results: Of 7,335 screened infants, 4,778 (65.1%) had blood cultures and were enrolled. Of these patients, 84 had bacteremia (1.8%; 95% confidence interval [CI] 1.4% to 2.2%). The prevalence of bacteremia in infants aged 28 days or younger (47/1,515) was 3.1% (95% CI 2.3% to 4.1%); in infants aged 29 to 60 days (37/3,246), 1.1% (95% CI 0.8% to 1.6%). Prevalence differed by week of age for infants 28 days of age and younger (0 to 7 days: 4/156, 2.6%; 8 to 14 days: 19/356, 5.3%; 15 to 21 days: 15/449, 3.3%; and 22 to 28 days: 9/554, 1.6%). The most common pathogens were Escherichia coli (39.3%; 95% CI 29.5% to 50.0%) and group B streptococcus (23.8%; 95% CI 16.0% to 33.9%). Bacterial meningitis occurred in 19 of 1,515 infants 28 days of age and younger (1.3%; 95% CI 0.8% to 2.0%) and 5 of 3,246 infants aged 29 to 60 days (0.2%; 95% CI 0.1% to 0.4%). Of 84 infants with bacteremia, 36 (42.9%; 95% CI 32.8% to 53.5%) had urinary tract infections (E coli 83%); 11 (13.1%; 95% CI 7.5% to 21.9%) had bacterial meningitis.

Comparative Study > Pediatrics. 2016 Aug;138(2):e20154381. doi: 10.1542/peds.2015-4381. Epub 2016 Jul 5.

Validation of the "Step-by-Step" Approach in the Management of Young Febrile Infants

Evidence for Age-Based Risk Stratification

Borja Gomez ¹, Santiago Mintegi ², Silvia Bressan ³, Liviana Da Dalt ⁴, Alain Gervaix ⁵, Laurence Lacroix ⁵, European Group for Validation of the Step-by-Step Approach

Affiliations + expand

PMID: 27382134 DOI: 10.1542/peds.2015-4381

Conclusions: We validated the Step by Step as a valuable tool for the management of infants with fever without source in the emergency department and confirmed its superior accuracy in identifying patients at low risk of IBI, compared with the Rochester criteria and the Lab-score.

> Pediatrics. 2019 Jul;144(1):e20183604. doi: 10.1542/peds.2018-3604. Epub 2019 Jun 5.

A Prediction Model to Identify Febrile Infants ≤60 Days at Low Risk of Invasive Bacterial Infection

Evidence for Age-Based Risk Stratification Paul L Aronson ^{1 2}, Veronika Shabanova ³, Eugene D Shapiro ^{3 4}, Marie E Wang ⁵, Lise E Nigrovic ⁶, Christopher M Pruitt ⁷, Adrienne G DePorre ⁸, Rianna C Leazer ⁹, Sanyukta Desai ¹⁰, Laura F Sartori ¹¹, Richard D Marble ¹², Sahar N Rooholamini ¹³, Russell J McCulloh ⁸, Christopher Woll ^{3 2}, Fran Balamuth ^{14 15}, Elizabeth R Alpern ¹², Samir S Shah ^{10 16}, Derek J Williams ¹⁷, Whitney L Browning ¹⁷, Nipam Shah ⁷, Mark I Neuman ⁶, Febrile Young Infant Research Collaborative

Objectives: To derive and internally validate a prediction model for the identification of febrile infants ≤60 days old at low probability of invasive bacterial infection (IBI).

Conclusions: Infants ≤60 days old with fever by history only, a normal urinalysis result, and an absolute neutrophil count <5185 cells per μL have a low probability of IBI.

Evidence for Age-Based Risk Stratification

> Arch Dis Child. 2019 Sep;104(9):874-878. doi: 10.1136/archdischild-2018-316191. Epub 2019 May 30.

Risk of invasive bacterial infections by week of age in infants: prospective national surveillance, England, 2010-2017

```
Shamez N Ladhani <sup>1 2</sup>, Katherine L Henderson <sup>3</sup>, Berit Muller-Pebody <sup>3</sup>, Mary E Ramsay <sup>1</sup>, Andrew Riordan <sup>4</sup>
```

Affiliations + expand

PMID: 31147318 DOI: 10.1136/archdischild-2018-316191

Results: There were 22 075 IBI episodes between 2010/2011 and 2016/2017. The lowest annual cases were in 2011/2012 (n=2 799; incidence, 412/100 000 population), increasing year-on-year to 3 698 cases in 2016/2017 (incidence, 552/100 000 population). The incidence was highest in the first week of life and then declined rapidly. In 2016/2017, compared with the first week of life, weekly IBI incidence was 92% lower at 8 weeks (IRR 0.08; 95% CI 0.06 to 0.10) and 96% lower at 16 weeks of age (IRR 0.04; 95% CI 0.03 to 0.06). In 2016/2017, *Escherichia coli* was the most prevalent pathogen responsible for IBI (n=592, 16.0%), followed by group B *Streptococci* (n=493, 13.3%), *Staphylococcus aureus* (n=400, 10.8%) and *Enterococci* (n=304, 8.2%). The other pathogens were individually responsible for <5% of total cases. There were differences in age distribution of the pathogens with increasing age.

Learning Objectives



"We are not makers of history. We are made by history."

> ~ Martin Luther King, Jr.



"There is nothing permanent except change."

~ Heraclitus

Updated Guidelines


"Do no dwell in the past, do not dream of the future, concentrate the mind on the present moment."

~ Buddha



"In the middle of a difficulty lies opportunity."


~ Einstein




Laboratory values of inflammation are considered elevated at the following levels: (1) procalcitonin >0.5 ng/mL, (2) CRP >20 mg/L, and (3) ANC >4000, >5200 per mm³

22 to 28 days old, well-appearing, no evident source of infection, nd temperature ≥ 38.0 °C Obtain urinalysis(8), a blood culture(9), and IMs(10). or SPA urine culture (8). Perform LP(11b).c May perform LP(11a). performed? obtained? CSF pleocytosis or uninterpretable? CSF pleocytosis or May administer parenteral antimicrobial(s)(12c). 2. Observe in hospital(13b). 1. Administer parenteral antimicrobial(s)(12a). 2. Observe in hospital(13b). bservation be at antimicrobial(s)(12d). antimicrobial(s)(12b). 2. Observe at home. Observe in hospital(13b). 3. Reassess in 24 hours (13a) 1. Discontinue antimicrobial(s)(14a,b) and Pathogen or source discharge hospitalized infant(14a) if all cultures Treat Infection(14c). are negative at 24 to 36 hours and HSV PCR is negative (if sent). 2. Follow for duration of illness

22 to 28 days old



Infant may be managed at home if parent and clinician agree that the following are present: reliable phone and transportation, parent willingness to observe and communicate changes in condition, and agreement to the infant being reevaluated in 24 hours.



IMs are considered abnormal at the following levels: (1) temperature >38.5°C, (2) procalcitonin >0.5 ng/mL, (3) CRP >20 mg/L, and (4) ANC >4000, >5200 per mm³

Learning Objectives



"We are not makers of history. We are made by history."

> ~ Martin Luther King, Jr.



"There is nothing permanent except change."

~ Heraclitus

Updated Guidelines

"Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment."

~ Buddha



"In the middle of a difficulty lies opportunity."

~ Einstein

Challenges

No infants < 7 days old

UTIs distort prediction models

Meningitis – uncommon – small sample size

Epidemiology of IBIs changing


Clinical appearance is subjective

Clinicians work in different settings

Variable access to newer diagnostic test and timely results

Families with a spectrum of knowledge and skills

Take Home Pearls





Inflammatory Markers are Your Friend!

(Especially for the 22–28-day old range)



E Coli is the MOST COMMON Pathogen

(Followed by Group B Strep)



New Guidelines are for WELL Appearing Infants

(Make wise choices)

References

- 1) Pantell R, Roberts KB, Adams WG, et al. Evaluation and management of well-appearing febrile infants 8 to 60 days old. *Pediatrics*. 2021; 148(2): e2021052228
- 2) Roberts KB. Young, febrile infants: a 30-year odyssey ends where it started. *JAMA*. 2004; 291(10): 1261-1262.
- 3) McCracken GH Jr. Group B streptococci: the new challenge in neonatal infections. *J Pediatr.* 1973; 82(4): 703-706.
- 4) Caspe WB, Chamudes O, Louie B. The evaluation and treatment of the febrile infant. *Pediatr Infect Dis.* 1983; 2(2): 131-135.
- 5) DeAngelis C, Joffe A, Wilson M, Willis E. latrogenic risks and financial costs of hospitalizing febrile infants. *Am J Dis Child*. 1983; 137(12): 1146-1149.
- 6) Dagan R, Powell KR, Hall CB, Menegus MA. Identification of infants unlikely to have serious bacterial infection although hospitalized for suspected sepsis. *J Pediatr*. 1985; 107(6): 855-860.

References (cont.)

- 7) Dagan R, Sofer S, Phillip M, Shachak E. Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serious bacterial infections. *J Pediatr*. 1988; 112(3): 355-360.
- 8) Baskin MN, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. *J Pediatr.* 1992 Jan; 120(1): 22-27.
- 9) Baker MD, Bell LM, Anver JR. Outpatient management without antibiotics of fever in selected infants. *N Engl J Med.* 1993 Nov 11; 329(20): 1437-1441.
- 10) Pantell RH, Newman TB, Bernzweig J, et al. management and outcomes of care of fever in early infancy. *JAMA*. 2004; 291(10): 1203-1212.
- 11) Greenhow TL, Hung YY, Pantell RH. Management and outcomes of previously healthy, full-term, febrile infants ages 7 to 90 days. *Pediatrics*. 2016; 138(6): e20160270
- 12) Powell EC, Mahajan PV, Rosevelt G, et al. Febrile Infant Working Group of the Pediatric Emergency Care Applied Research Network (PECARN). Epidemiology of bacteremia in febrile infants aged 60 days and younger. *Ann Emerg Med*. 2018; 71(2): 211-216.

References (cont.)

- 13) Mintegi S, Bressan S, Gomez B, et al. Accuracy of sequential approach to identify young febrile infants at low risk for invasive bacterial infection. *Emerg Med J.* 2014; 31(e1): e19-e24.
- 14) Gomez B, Mintegi S, Bressan S, Da Dalt L, Gervaix A, Lacroix L. European Group for Validation of the Step-by-Step Approach. Validation of the "Step-by-Step" approach in the management of young febrile infants. *Pediatrics*. 2016; 138(2): e20154381
- 15) Aronson PL, Shabanova V, Shapiro ED, et al. Febrile Young Infant Research Collaborative. A prediction model to identify febrile infants ≤ 60 days at low risk of invasive bacterial infection. *Pediatrics*. 2019; 144(1): e20183604.
- 16) Ladhani SN, Henderson KL, Muller-Pebody B, Ramsay ME, Riordan A. Risk of invasive bacterial infections by week of age in infants: prospective national surveillance, England, 2010-2017. *Arch Dis Child*. 2019; 104(9): 874-878.
- 17) Jain S, Cheng J, Alpern ER, et al. Management of febrile neonates in US pediatric emergency departments. *Pediatrics*. 2014; 133(2): 187-195.

References (cont.)

- 18) Aronson PL, Thurm C, Alpern ER, et al. Febrile Young Infant Research Collaborative. Variation in care of the febrile young infant < 90 days in US pediatric emergency departments. *Pediatrics*. 2014; 134(4): 667-677.
- 19) Schroeder AR, Harris SJ, Newman TB. Safely doing less: a missing component of the patient safety dialogue. *Pediatrics*. 2011; 128(6): e1596-1597.
- 20) Hernandez-Bou S, Trenchs V, Vanegas MI, Valls AF, Luaces C. Evaluation of the bedside Quickread go CRP test in the management of febrile infants at the emergency department. *Eur J Clin Microbiol Infect Dis.* 2017; 36(7):1205-1211.
- 21) England JT, Del Vecchio MT, Aronoff SC. Use of serum procalcitonin in evaluation of febrile infants: a meta-analysis of 2317 patients. *J Emerg Med*. 2014; 47(6): 682-688.
- 22) Milcent K, Faesch S, Gras-Le Guen C, et al. Use of procalcitonin assays to predict serious bacterial infection in young febrile infants. *JAMA Pediatr*. 2016; 170(1): 62-69.

Questions?

